Fianlimab is a monoclonal antibody commercialized by Regeneron Pharmaceuticals, with a leading Phase III program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 8 clinical trials, of which 5 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Fianlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Fianlimab is expected to reach an annual total of $263 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Fianlimab is under development for the treatment of metastatic melanoma, acral lentiginous melanoma, non-small cell lung cancer, squamous non-small cell lung cancer, advanced hematological malignancies including lymphoma and solid tumors including breast cancer, breast cancer, lung cancer, melanoma and thyroid cancer. The drug candidate acts by targeting the checkpoint inhibitor (LAG-3). The therapeutic candidate is developed based on VelociGene and VelocImmune platform technology. It is administered through intravenous route.
Regeneron Pharmaceuticals Overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
The company reported revenues of (US Dollars) US$12,172.9 million for the fiscal year ended December 2022 (FY2022), a decrease of 24.3% over FY2021. In FY2022, the company’s operating margin was 38.9%, compared to an operating margin of 55.7% in FY2021. In FY2022, the company recorded a net margin of 35.6%, compared to a net margin of 50.2% in FY2021. The company reported revenues of US$3,162.1 million for the first quarter ended March 2023, a decrease of 7.4% over the previous quarter.
For a complete picture of Fianlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.